AU2011246503B2 - Improved cell culture medium - Google Patents

Improved cell culture medium Download PDF

Info

Publication number
AU2011246503B2
AU2011246503B2 AU2011246503A AU2011246503A AU2011246503B2 AU 2011246503 B2 AU2011246503 B2 AU 2011246503B2 AU 2011246503 A AU2011246503 A AU 2011246503A AU 2011246503 A AU2011246503 A AU 2011246503A AU 2011246503 B2 AU2011246503 B2 AU 2011246503B2
Authority
AU
Australia
Prior art keywords
cell culture
cells
medium
culture medium
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011246503A
Other languages
English (en)
Other versions
AU2011246503A1 (en
Inventor
Christian Leist
Petra Meissner
Jorg Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44074260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2011246503(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2011246503A1 publication Critical patent/AU2011246503A1/en
Application granted granted Critical
Publication of AU2011246503B2 publication Critical patent/AU2011246503B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/005—Protein-free medium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2011246503A 2010-04-26 2011-04-25 Improved cell culture medium Active AU2011246503B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32783610P 2010-04-26 2010-04-26
US61/327,836 2010-04-26
PCT/EP2011/056508 WO2011134920A1 (en) 2010-04-26 2011-04-25 Improved cell culture medium

Publications (2)

Publication Number Publication Date
AU2011246503A1 AU2011246503A1 (en) 2012-11-22
AU2011246503B2 true AU2011246503B2 (en) 2013-09-26

Family

ID=44074260

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011246503A Active AU2011246503B2 (en) 2010-04-26 2011-04-25 Improved cell culture medium

Country Status (17)

Country Link
US (2) USRE48864E1 (enExample)
EP (1) EP2563904B1 (enExample)
JP (3) JP6347949B2 (enExample)
KR (1) KR101828623B1 (enExample)
CN (1) CN102858952B (enExample)
AU (1) AU2011246503B2 (enExample)
BR (1) BR112012027282B1 (enExample)
CA (1) CA2797356C (enExample)
DK (1) DK2563904T3 (enExample)
ES (1) ES2533074T3 (enExample)
IL (1) IL222452B (enExample)
MX (1) MX2012012526A (enExample)
PL (1) PL2563904T3 (enExample)
PT (1) PT2563904E (enExample)
RU (1) RU2644651C2 (enExample)
SG (1) SG185038A1 (enExample)
WO (1) WO2011134920A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX353340B (es) 2006-09-13 2018-01-09 Abbvie Inc Mejoras de cultivos celulares.
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TW201024318A (en) 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
SG195577A1 (en) 2008-10-20 2013-12-30 Abbott Lab Viral inactivation during purification of antibodies
PT2563904E (pt) * 2010-04-26 2015-05-12 Novartis Ag Meio de cultura de células aperfeiçoado
BR112012027434B1 (pt) 2010-04-26 2020-09-29 Novartis Ag Processo para produção de um polipeptídeo recombinante compreendendo uma fase de produção
CN103221534B (zh) * 2010-12-07 2016-05-18 弗·哈夫曼-拉罗切有限公司 进料混合装置及其用途
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
SG11201401562RA (en) 2011-10-18 2014-09-26 Coherus Biosciences Inc Etanercept formulations stabilized with sodium chloride
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US20130281355A1 (en) * 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
JP6271536B2 (ja) 2012-07-09 2018-01-31 コヒラス・バイオサイエンシズ・インコーポレイテッド 肉眼不可視粒子の著しい低減を示すエタネルセプト製剤
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
AU2013315750B9 (en) 2012-09-11 2018-11-15 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
KR20150129033A (ko) 2013-03-14 2015-11-18 애브비 인코포레이티드 저 산성 종 조성물 및 이의 제조 및 사용 방법
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US10196601B2 (en) 2013-08-20 2019-02-05 Lek Pharmaceuticals D.D. Cell culture medium and process for controlling α-amidation and/or C-terminal amino acid cleavage of polypeptides
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
DK3351620T3 (da) * 2013-10-11 2020-10-26 Regeneron Pharma Metabolsk optimeret cellekultur
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015116820A1 (en) 2014-01-30 2015-08-06 Coherus Biosciences, Inc. Perfusion media
EP4332231A3 (en) 2014-04-29 2024-05-29 Novartis AG Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
ES2733298T3 (es) 2014-07-18 2019-11-28 Sandoz Ag Cuantificación de TNFR2:Fc plegado erróneamente
CN108495926A (zh) * 2015-12-17 2018-09-04 生命技术公司 用于细胞培养的颗粒及其制备方法
CA3019753C (en) * 2016-04-05 2021-10-26 Pfizer Inc. Cell culture process
KR102604992B1 (ko) * 2017-03-31 2023-11-24 베링거 인겔하임 인터내셔날 게엠베하 관류 배지
SG11201909087PA (en) * 2017-03-31 2019-10-30 Boehringer Ingelheim Int Perfusion medium
BR112021021349A2 (pt) 2019-04-26 2022-02-01 Allogene Therapeutics Inc Métodos de fabricação de células car t alogênicas
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
KR20220097421A (ko) * 2019-11-05 2022-07-07 아지노모토 가부시키가이샤 단백질의 제조 방법
KR20230002642A (ko) * 2020-04-15 2023-01-05 제넨테크, 인크. 접종 전 배지를 처리하는 방법
US20230313259A1 (en) * 2020-08-14 2023-10-05 Bristol-Myers Squibb Company Manufacturing process for protein
UY39484A (es) 2020-11-02 2022-06-30 Novartis Ag Inhibidores de interleucina-17
CN114606200B (zh) * 2022-02-10 2025-07-18 上海迈邦生物科技有限公司 Sp2/0细胞培养基及生产重组犬细小病毒单克隆抗体的方法
WO2026009803A1 (ja) * 2024-07-05 2026-01-08 国立大学法人九州大学 ヘパリン様物質を製造する方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026445A1 (en) * 2004-08-27 2006-03-09 Wyeth Research Ireland Limited Production of polypeptides

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
DE3871206D1 (de) 1987-03-24 1992-06-25 Grace W R & Co Basisnaehrmedium fuer eine zellkultur.
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5135866A (en) 1989-03-03 1992-08-04 W. R. Grace & Co.-Conn. Very low protein nutrient medium for cell culture
CA2001550A1 (en) 1989-03-03 1990-09-03 Aaron H. Heifetz Very low protein nutrient medium for cell culture
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
JPH0789908B2 (ja) 1991-02-28 1995-10-04 倉敷紡績株式会社 動物細胞培養用無血清培地
GB9118664D0 (en) 1991-08-30 1991-10-16 Celltech Ltd Cell culture
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5830761A (en) 1995-06-07 1998-11-03 Genetics Institute, Inc. Medium and methods for culturing mammalian cho cells
EP2243827B2 (en) * 1996-08-30 2017-11-22 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
EP1757700A3 (en) 1999-04-26 2009-03-11 Genentech, Inc. Cell culture process for glycoproteins
AU4980200A (en) 1999-05-27 2000-12-18 Pharmacia & Upjohn Company Methods and compositions for measuring ion channel conductance
AT409379B (de) * 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
WO2001048147A1 (en) 1999-12-28 2001-07-05 Iso Tis N.V. Cell culture medium containing growth factors and l-glutamine
CA2438148A1 (en) 2001-02-15 2002-08-29 Centocor, Inc. Chemically defined medium for cultured mammalian cells
WO2002101019A2 (en) 2001-06-13 2002-12-19 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
WO2004008100A2 (en) 2002-07-15 2004-01-22 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
AU2003300276B2 (en) 2002-12-23 2010-07-01 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
GB0304799D0 (en) * 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
DE10338536A1 (de) 2003-08-19 2005-04-07 Bircher Reglomat Ag Verfahren zum Betreiben eines Radarsensors
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
EP1937798A4 (en) 2005-04-15 2009-05-13 Univ Columbia CHEMICALLY DEFINED CULTURAL MEDIA FOR THE EXPANSION AND DIFFERENTIATION OF EPIDERMIC CELLS AND USES THEREOF FOR THE IN VITRO FARMING OF HAIRFOLLICLES
US20070231895A1 (en) 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
CA2668771C (en) * 2006-11-08 2016-03-15 Wyeth Rationally designed media for cell culture
PT2563904E (pt) * 2010-04-26 2015-05-12 Novartis Ag Meio de cultura de células aperfeiçoado

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026445A1 (en) * 2004-08-27 2006-03-09 Wyeth Research Ireland Limited Production of polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Scott BS et al, Experimental Neurology, 1971, 31(2):183-188 *

Also Published As

Publication number Publication date
CA2797356C (en) 2020-12-29
PT2563904E (pt) 2015-05-12
ES2533074T3 (es) 2015-04-07
CN102858952A (zh) 2013-01-02
KR101828623B1 (ko) 2018-02-12
US9428727B2 (en) 2016-08-30
US20130122543A1 (en) 2013-05-16
IL222452B (en) 2019-03-31
SG185038A1 (en) 2012-11-29
EP2563904B1 (en) 2015-01-21
BR112012027282A2 (pt) 2015-09-22
PL2563904T3 (pl) 2015-06-30
DK2563904T3 (en) 2015-04-07
RU2012150346A (ru) 2014-06-10
AU2011246503A1 (en) 2012-11-22
CA2797356A1 (en) 2011-11-03
RU2644651C2 (ru) 2018-02-13
USRE48864E1 (en) 2021-12-28
EP2563904A1 (en) 2013-03-06
JP2017012180A (ja) 2017-01-19
RU2018101201A3 (enExample) 2021-05-27
CN102858952B (zh) 2015-10-14
JP2013524825A (ja) 2013-06-20
JP7034991B2 (ja) 2022-03-14
RU2018101201A (ru) 2019-02-21
BR112012027282B1 (pt) 2020-09-29
JP6603628B2 (ja) 2019-11-06
MX2012012526A (es) 2012-11-23
KR20130058699A (ko) 2013-06-04
JP2019216728A (ja) 2019-12-26
JP6347949B2 (ja) 2018-06-27
WO2011134920A1 (en) 2011-11-03
IL222452A0 (en) 2012-12-31

Similar Documents

Publication Publication Date Title
US9428727B2 (en) Cell culture medium
AU2011246502B2 (en) Improved cell cultivation process
US9243224B2 (en) Cell culture medium
RU2798069C2 (ru) Улучшенная среда для культивирования клеток

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)